$6.15
+0.60(10.81%)
Mkt Cap $51M
$0.80
$7.78
52-Week Range
At a Glance
AI-generated8-K
Edesa Biotech, Inc. reported financial results for the three months ended December 31, 2025, with total operating expenses of $2.3 million, net loss of $2.2 million or $0.28 per common share, cash and cash equivalents of $12.1 million, and working capital of $12.0 million. The company progressed EB06 manufacturing for a Phase 2 vitiligo study starting midyear 2026 and is evaluating paridiprubart Phase 3 data.$51M
Market Cap
—
Revenue
-$8M
Net Income
Employees16
Fundamentals
How The Business Makes Money
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001540159
ISINCA27966L3065
CUSIP27966L108
Phone289-800-9600
Address100 Spy Court, Markham, ON, L3R 5H6, CA
SEC EDGAR